GLOBAL CARE Initiative (GCI) is an outstanding consortium of 5 Carnot Institutes that covers 4 therapeutic fields of major interest in human health markets: oncology, ophthalmology, infectious diseases and neurology.
It puts together up to 2,500 researchers and a wide technical assets and expertise and drives a budget of US$ 42 millions (€ 31 millions) for business development & research.
Based in France (Paris & Lyon), GLOBAL CARE Initiative is an efficient and high quality springboard toward International for RTO, Pharma and Biotech.
Supported by our past experience in translational research and in property management and by the fame of its members, GCI targets the international health market on:
- emerging imaging technologies
- innovative diagnostic tools
- therapeutic advances.
GCI is gathering up to 2,500 researchers in life science for offering enlarged opportunities to our industrial and research partners worldwide. Bringing greater visibility to our R&D offers, GCI aims at mobilizing multi-disciplinary researchers in response to R&D needs.
The 5 consortium members:
- The Institut Carnot Curie Cancer - Paris
- The Institut Carnot Spine & Brain Institute (ICM) - Paris
- The Institut Carnot Pasteur MI - Paris
- The Institut Carnot CALYM (consortium for the acceleration of innovation and its transfer to the field of Lymphoma) - Lyon
- The Institut Carnot Voir & Entendre - Paris
GLOBAL CARE Initiative is funded by the French Agence Nationale de la Recherche (National Agency for Research) and Investissement d’Avenirs (investments in the future) on an agreement based on a decision by the Office of the French Prime Minister (ANR-11-CNRT-00-04).
An identity built on a prestigious history
- 15 Nobel Prizes
- up to 2,500 researchers
- wide technical assets and expertise (15 Nobel prizes)
- a global budget of US$ 42millions (€ 31 millions) for business development & research
- based in Paris & Lyon, France, Europe
- financial following of more than 300 partnership contracts per year
- about 5,000 active patents
- more than 35 startups created
- more than € 80 millions in terms of revenue per year (patent licensing, collaboration, services…)